This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.
Publications
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension
International Journal of Molecular Sciences – August 2023
Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension
European Respiratory Journal – June 2022
TORREY, a Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Pulmonary Circulation – October 2021
Scientific Congresses
Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension
PVRI - January 2024
Effects of inhaled Seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
PVRI - January 2024
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging sub-study
PVRI - January 2024
See More
Seralutinib MOA Video
A targeted approach to the proliferation, fibrosis, and inflammation associated with Pulmonary Arterial Hypertension
Targeting the underlying mechanisms of Pulmonary Arterial Hypertension